UBS lowered the firm’s price target on Alkermes to $23 from $25 and keeps a Sell rating on the shares. UBS believes Alkermes stock will likely continue to underperform, as the FY24 guidance seems unachievable and there are no pipeline catalysts remaining for the year, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Biotech Alert: Searches spiking for these stocks today
- Alkermes narcolepsy drug ‘could be best-in-class,’ says Mizuho
- Alkermes price target raised to $50 at Jefferies after ‘excellent’ NT2 data
- Alkermes narcolepsy data better than expected, says Stifel
- Alkermes Reveals Promising Phase 1b Study Results